This revision of the TSE (Transmissible Spongiform Encephalopathy) note for guidance has been
undertaken to introduce, inter alia, risk assessment into the regulatory compliance process, to provide
clarification on a variety of terms and classifications, and to take into account advances in scientific
knowledge, Community legislation and rules affecting the authorisation of medicinal products for
human or veterinary use.